FOI release

Yellow Card reports for unlicensed/falsified peptide products

Case reference FOI2026/00876

Received 8 August 2026

Published 8 September 2026

Request

Under the Freedom of Information Act 2000, I would like to request the following information held by the MHRA. 1. The total number of Yellow Card reports received since 1 January 2024 that relate, in whole or in part, to unlicensed, falsified, or 'research use only' peptide products used by humans for weight loss, muscle building, or aesthetic purposes, including but not limited to retatrutide, tirzepatide (where recorded as unlicensed or counterfeit), BPC-157, and similar compounds. 2. A breakdown by year and, where recorded, by outcome (e.g. hospitalisation, fatality, non-serious). I am not requesting any personal data, case narratives, or information that would identify an individual reporter or patient.

Response

See attached

Documents

• FOI2026_00876 (redacted).pdf (577.0 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.